Cite
APA Citation
Teramachi, J., Hiasa, M., Oda, A., Harada, T., Nakamura, S., Amachi, R., Tenshin, H., Iwasa, M., Fujii, S., Kagawa, K., Miki, H., Kurahashi, K., Yoshida, S., Endo, I., Haneji, T., Matsumoto, T., & Abe, M. (2018). pim‐2 is a critical target for treatment of osteoclastogenesis enhanced in myeloma. British journal of haematology, 180, 581–585. http://access.bl.uk/ark:/81055/vdc_100057290294.0x00005b